Organic Nitrates as a Theraputic Agent

2330 Words5 Pages

Introduction
Organic nitrates (ORNs) have been used for the prevention and treatment of myocardial ischemia and angina pectoris for approximately 130 years. They are polyolesters of nitric acid (RONO2) that can be classified into two categories: high potency ORNs that contain three or four nitrate groups, such as nitroglycerin (NTG) and pentaerythritol tetranitrate (PETN); low potency ORNs containing one or two nitrate groups, for instance, isosorbide dinitrate (ISDN), isosorbide-2-mononitrate (IS-2-MN), isosorbide-5-mononitrate (IS-5-MN), and nicorandil (Munzel et al., 2005). ORNs are bioactivated to produce nitric oxide (NO) by various enzymes, including cytochrome P450 (CYPs), xanthine oxidase (XO), glutathione-S-transferases (GSTs), aldehyde dehydrogenases (ALDHs), and so on (Table 1). Released NO activates soluble guanylyl cyclase (sGC), which converts guanosine-5’-triphosphate (GTP) to 3’, 5’-cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. Elevated intracellular cGMP inhibits the entry of calcium into the cell, and hence causing smooth muscle relaxation and vasodilation. Therefore, ORNs’ vasodilatory effect is coupled to their metabolism in vascular smooth muscle. NO acts predominantly on venous capacitance vessels, thereby reduces venous pressure and ventricular preload, which decrease myocardial wall tension and oxygen demand by heart (Munzel and Gori, 2013).
Although several enzymes have been identified to metabolize and bioactivate ORNs, the corresponding mechanisms still remain incompletely understood, especially regarding the precursor of NO and the link between NO and activation of sGC. Investigation of these hurdles were impeded by limited tools to measure labile reaction intermediates (e.g. OR...

... middle of paper ...

...oic acid (Packer et al., 1987; Watanabe et al., 1998b; Watanabe et al., 1998a; Gori et al., 2001; Dudek et al., 2008). Additionally, inducer of ALDH2, ALDA-1, has been shown to prevent tolerance and minimize cardiac damage via increasing ALDH2 level (Chen et al., 2008).
Conclusions
Organic nitrates have been served as the exogenous source of nitric oxide and an excellent therapeutic agent for various cardiovascular diseases for more than a century. Although they are rapid acting and relatively safe, chronic application of ORNs induces pharmacological tolerance and endothelial dysfunction. Investigation of the metabolism (bioactivation and clearance) of ORNs has allowed us understand the underlying mechanisms of NO generation, tolerance, and potential toxic effects, and therefore provide corresponding avoidance strategies and extend the use of this powerful agent.

Open Document